Update from the COVID-19 IBD databas

Total:  Number of cases Reported to date 239

Total # of deaths reported 11

 

 

 

 

Cases and outcomes by age

 

Total N

Outpatient only (n, %)

Hospitalized (n, %)

ICU (n, %)

Ventilator (n, %)

Death (n, %)

ICU/Ventilator/Death (n, %)

0-10 years 

1

1

100%

0

0%

0

0%

0

0%

0

0%

0

0%

11-20 years 

11

11

100%

0

0%

0

0%

0

0%

0

0%

0

0%

21-30 years 

55

43

78%

12

22%

1

2%

1

2%

0

0%

1

2%

31-40 years 

55

43

78%

11

20%

1

2%

1

2%

1

2%

1

2%

41-50 years 

42

30

71%

12

29%

2

5%

2

5%

1

2%

2

5%

51-60 years 

30

20

67%

10

33%

1

3%

1

3%

1

3%

2

7%

61-70 years 

23

18

78%

5

22%

2

9%

2

9%

1

4%

3

13%

71-80 years 

9

3

33%

6

67%

0

0%

0

0%

2

22%

2

22%

81-90 years 

6

0

0%

6

100%

0

0%

0

0%

4

67%

4

67%

>=90 years 

5

3

60%

2

40%

0

0%

0

0%

1

20%

1

20%

 

 

Outcomes By Medication

 

Total N

Outpatient only (n, %)

Hospitalized (n, %)

ICU (n, %)

Ventilator (n, %)

Death (n, %)

Sulfasalazine/mesalamine

44

23

52%

21

48%

4

9%

4

9%

5

11%

Budesonide 

8

5

63%

3

38%

0

0%

0

0%

0

0%

Oral/parenteral steroids 

17

4

24%

13

76%

3

18%

3

18%

4

24%

6MP/azathioprine 

37

25

68%

12

32%

2

5%

2

5%

1

3%

Methotrexate 

10

4

40%

6

60%

0

0%

0

0%

1

10%

Anti-TNF D

113

90

80%

22

19%

1

1%

1

1%

3

3%

Anti-TNF + 6MP/AZA/MTX 

19

10

53%

9

47%

1

5%

1

5%

2

11%

Anti-integrin *

21

17

81%

4

19%

0

0%

0

0%

0

0%

IL 12/23 inhibitor **

16

16

100%

0

0%

0

0%

0

0%

0

0%

JAK inhibitor ***

7

6

86%

1

14%

1

14%

1

14%

1

14%

Other IBD medication 

11

5

45%

6

55%

1

9%

1

9%

0

0%

Outcomes By Medication

 

         D Anti TNF= Remicade (infliximab), Humira (adalimunab), Simponi (golimunab) Cimzia (certolizumzab)

* Alpha integrin= Entyvio (Vedolizumab)

**IL 12/23 inhibitor= Stelara (Ustekinumab)

***JAK inhibitor= Xeljanz (tofacitinib)

 

 

 

Take home points:

 

  1. The data above does seem to indicate that being on multiple immunosuppressant medications or steroids (areas highlighted in yellow) is associated with increased risk.

 

  1. If you are taking multiple medications and/or steroids you should call your doctor to discuss.

 

  1. It should be noted that the two deaths occurring inpatients on methotrexate and xeljanz were taking either an anti-tnf agent or steroids in addition to these medications.

 

  1. The 5 deaths seen in patients on mesalamine appear to be due that these were mainly older patients: four were 80 or older, the fifth was 69.

 

You Might Also Enjoy...

Status of Crohn's and Colitis Patients and COVID-19

The American Gastroenterological Association is maintaining an International Registry of patients with IBD who have been diagnoses with COVID-19. Thanks to Dr. Ryan Ungaro, our colleague at Mount Sinai who is spearheading this effort! See below: